All cancers depend upon mutations in critical genes, which confer a selective advantage to the tumour cell. Knowledge of these mutations is crucial to understanding the biology of cancer initiation and progression, and to the development of targeted therapeutic strategies. The key to understanding the contribution of a disease-associated mutation to the development and progression of cancer, comes from an understanding of the consequences of that mutation on the function of the affected protein, and the impact on the pathways in which that protein is involved.
Introduction
In most diseases of genetic origin, the disease phenotype can usually be attributed to a small number of defined mutations, which once located are readily distinguished from the essentially wild-type genetic background [1] .
Cancer is also fundamentally a genetic disease, with the phenotype arising by somatic acquisition of a set of defined 'hallmark' mutations [2] . These exert their effect by activating oncogenes and/or inactivating tumour suppressors, one or more of which may already be mutated in the germline in inherited cancer predispositions syndromes.
Acquisition of the genetic changes that confer hallmark traits of invasive cancer depends on loss of genetic stability early in the tumour cell lineage typically initiated by a defect in the DNA damage response (DDR) [3] .
Paradoxically, the inherent genetic instability that gives tumours their evolutionary plasticity underlies their sensitivity to the genotoxic drugs and radiation that constitute many first-line cancer therapies. An important consequence of this genetic instability is the presence of large numbers of mutational changes in the genomes of tumours as compared to untransformed cells from the same individual [4] . The overwhelming majority of these changes may be inconsequential in terms of driving the cancer phenotype, but generate a high level of mutational 'noise' within which the significant driving mutations may be very difficult to identify.
There has been a substantial increase in understanding of the many pathways that can drive the hallmark traits of cancer in the last few years [5] , and many specific inhibitors of the proteins that constitute those pathways have been developed. Together with the development of rapid and low-cost genome sequencing, there is now the real prospect of 'personalised' drug therapies precisely targeted to the idiosyncratic regulatory malfunctions resulting from the mutations that drive an individual cancer [6] , so long as these can be distinguished from the substantial background of irrelevant 'passenger' mutations, so that the genotype can be used to predict the phenotype .
Given the large numbers of mutations typically observed [7] experimental determinations of the consequences on protein function of the individual mutations observed in a cancer genome are not realistic, and computational approaches are required.
Identifying Driver Genes
These are several statistical approaches (eg [8, 9] ) that identify significantly mutated genes within large cohorts of sequenced tumours. These approaches are very good at identifying highly recurrent mutated genes but as yet, the data sets are not large enough to have the statistical power to detect low frequency mutated genes that contribute to the initiation and progression of cancer. This can pose a problem because although a few genes are highly mutated, the majority of somatic mutations occur in genes that are infrequently mutated [10, 11] . In oncogenes, an increase in activity, or a change of function is required for tumorigenesis. They tend to exhibit a molecularly dominant mode of action, and usually only one defective copy of the gene is required to provide an oncogenic phenotype. This is exhibited in BRAF where V600E activating mutations constitutively activates BRAF in malignant melanoma [14] , or in BCR-ABL in chronic myelogenous leukaemia where a translocation constitutively activates ABL-kinase.
Characteristics of Tumour Suppressors and Oncogenes
Missense mutations in tumour suppressors can result in its loss of function in a variety of manners including loss of stability of the protein or the disruption of a crucial ligand/DNA/protein-binding site [15] . In cohorts of tumours, these mutations are often liberally dispersed along the length of the gene, as protein function can be disrupted by mutations at a multitude of positions [16] .
Conversely, in oncogenes, driver missense mutations tend to cluster at distinct locations in the amino acid sequence impacting on sites of proteinprotein interaction, allosteric regulation, post-translational modification or ligand-binding. Often only a very few, specific mutations can lead to activation of the protein product or a change of a protein function [16] .
Identifying driver mutations
Sequence and structural data have been utilised to predict whether a missense mutation or a small insertion or deletion could be disease-causing using a variety of approaches. Sequence conservation is used to predict which mutations can be tolerated within a protein structure, and similarly, protein structures have been used for estimating how disruptive a missense mutation may be [15, [17] [18] [19] [20] . Techniques originally developed to predict the consequences of amino-acid changes observed in SNPs and Mendelian genetic diseases, have been applied to cancer mutations, but have often failed to provide sufficiently reliable prediction.
More recently algorithms have been specifically developed to distinguish cancer-associated somatic driver mutations from passenger mutations. These include profile-based methods for assessing missense mutations (eg [21] [22] [23] [24] ), and machine learning algorithms for assessing the pathogenicity of missense mutations [25] and indels [26] .
Approaches to distinguish between tumour suppressors and oncogenes
As the mutational patterns observed in cohorts of tumour samples clearly differ between tumour suppressor and oncogenes, several groups have used this information to automatically distinguish between them. For instance, Vogelstein's 20:20 rule [16] states that if 20% of all mutations observed in a gene within a cohort of tumour samples are truncations, then that gene is likely to be a tumour suppressor, where as if 20% of all missense mutations occur at a single position in the sequence, the gene is predicted to be an oncogene. These types of patterns have also been included in machine learning algorithms to automatically distinguish between tumour suppressors and oncogenes (eg [27] ) using data from whole exome sequencing.
MOKCa database
The MOKCa database [28] (http://strubiol.icr.ac.uk/extra/mokca/) was developed to structurally and functionally annotate, and where possible predict, the phenotypic consequences of disease-associated mutations in protein kinases implicated in cancer. We have recently extended the database to include all the proteins from the human genome that are mutated in cancer (see supplementary figure 1 ).
Somatic mutation data from the COSMIC database [7] have been mapped to their position in UniProt sequences [29] . Each mutation is described by its alteration to the protein structure, eg V600E. When a mutation has been reported on more one occasion, it is stored as an "aggregate" mutation and the number of observations of the aggregate mutation is recorded. Different genetic changes that result in the same protein coding mutation are presented together at the protein level and each disease type in which this mutation has been recorded is also presented on the protein overview page.
Functional annotations for each protein are displayed. These include the identification and position of Pfam domain assignments within the protein sequence [30] , and the positions of residues effected by post-translational modifications including phosphorylation, glycosylation, and ubiquitination [31] .
Gene Ontology (GO) annotations have also been obtained for each protein [32] .
Structural Mapping of Mutations
The amino acid sequence for every Pfam-annotated domain for which COSMIC records a cancer-associated mutation has been scanned against the Protein Data Bank (PDB) [33] using BLAST/PSI-BLAST [34] , to map the mutation onto the protein structure of the affected human protein domains where the structure has been experimentally determined, or onto the most closely related homologous structure where the experimental structure is not known.
The positions of the individual mutations can be viewed on the mutation web page using the Jmol application [35] , and the multiple sequence alignment between the query domain and the PDB template is displayed using Jalview [36] .
Development of web-interface
The new web-interface for MOKCa database can accessed at http://strubiol.icr.ac.uk/extra/mokca/ (see figure 1 ) and can be searched by gene name or by UniProt accession [29] .
Users can also browse the data using gene names either exploring the complete genome or our curated sets of genes that are implicated in cancer.
These include, protein kinases, oncogenes and tumour suppressors, proteins involved in the DNA damage response (DDR) [37] and those proteins that are current targets of chemotherapy and personalised cancer medicine regimes (drug targets) [38] .
Activating mutations in oncogenes
Analysis of data in the MOKCa database suggests that although there are a large number of ways to inactivate the protein product of a gene, there are probably only a limited number of ways that small mutations (missense, truncations, indels) are able to activate them. We have identified several common mechanisms of activation -some of these are highlighted below. Recent molecular dynamic simulations support this model, suggesting that the V600E mutation increases the energy barrier of the transition from the active to inactive conformation, trapping B-Raf in the active state. They also suggest that an increase in the flexibility of the activation loop may also speed-up phosphorylation [39] .
Activating mutations in protein kinases
Dependant on their location within the kinase domain, missense mutations will often be better tolerated in one or other conformation of the protein kinase resulting in an alteration of the conformational equilibrium and constitutive activation (or in some cases deactivation) of the protein kinase.
Another observed mechanism for the constitutive activation of protein kinases is the loss of inhibitory phosphorylation sites. These include the auto inhibitory phosphorylation sites in KIT at position Y823 (D/C/N mutations) and the S259A mutation in the PKC phosphorylation site in Raf1, that mediates inhibitory 14-3-3 protein [40] . Tyrosine receptor kinases can also be activated by dimerization of the extracellular domains resulting in ligand-independent activation of the receptor. This is observed in FGFR2 by mutations R203C and W290C in the immunoglobulin-like (Ig-like) domains [41, 42] .
Oncogenic mutations in isocitrate dehydrogenases
Mutations in isocitrate dehydogenases are also thought to contribute to the progression of cancer by altering the conformation of the protein. IDH1 and IDH2 catalyse the oxidative carboxylation of isocitrate to α-ketoglutarate.
Mutational hotspots at R132H in IDH1, and R140Q and R172K in IDH2 alter the progression of this reaction. Recent structural work suggests that the R132H IDH1 mutation hampers the conformational change from the initial isocitrate binding state to the pre-transition state, thus causing an impairment of enzyme function [43] . This alters the progression of this reaction causing the oncometabolite R(-)-2-hydroxyglutarate to be formed. R(-)-2hydroxyglutarate is implicated in genomic hypermethylation, leading to histone methylation, genomic instability, and finally malignant transformation [44] .
Domain-based approaches at identifying mutational hotspots
Although most of the analysis of cancer mutations is based around a gene centric view, a few studies have focused on domain-based analyses [45, 46] [50] and they may be particularly fruitful when studying mechanisms of activation of proteins. Larger proteins comprise recognizable smaller sequence domains, which recur in other proteins in various combinations.
These domains may be thought of as units of evolution, creating protein domain families, and have evolved from a common ancestor. As a domain can exist across multiple proteins with conserved function and structure, it follows that similarly located mutations across different proteins in the same domain should have similar effects on the function of that domain.
Proteome-wide analyses have been performed to identify domains enriched in missense mutations [45, 47] [50] and to identify domain-centric positions of hotspot missense mutations [48, 49] [50]. These studies focused exclusively on missense mutation and as yet, little attempt was to use these data to distinguish between activating and loss of function mutations in the majority of cases.
We are currently mapping all simple small mutations (missense, truncations and indels) from over thirty different types of cancer to equivalent positions in multiple sequence alignments of protein domains. These data are being used to identify domain-centric mutational hotspots and can be accessed through the MOKCa database.
Using the biological knowledge associated with protein domains, such as structural information and evolutionary conservation, will enable us to understand the functional consequences of infrequent mutations in wellcharacterised domain families and will facilitate additional insights into the roles of these mutations in cancer. 
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